Abstract:Abstract Deubiquitinases (DUBs) play important roles in various human cancers and targeting DUBs is considered as a novel anticancer therapeutic strategy. Overexpression of ubiquitin specific protease 7 and 22 (USP7 and USP22) are associated with malignancy, therapy resistance, and poor prognosis in many cancers. Although both DUBs are involved in the regulation of similar genes and signaling pathways, such as histone H2B monoubiquitination (H2Bub1), c-Myc, FOXP3, and P53, the interdependence of USP22 and USP7 expression has never been described. In the study, we found targeting USP7 via either siRNA-mediated knockdown or pharmaceutical inhibitors dramatically upregulates USP22 in cancer cells. Mechanistically, the elevated USP22 occurs through a transcriptional pathway, possibly due to desuppression of the transcriptional activity of SP1 via promoting its degradation upon USP7 inhibition. Importantly, the elevated USP22 leads to significant activation of downstream signal pathways including H2Bub1 and c-Myc, which may potentially enhance cancer malignancy and counteract the anticancer efficacy of USP7 inhibition. Importantly, targeting USP7 further suppresses the in vitro proliferation of USP22-knockout (USP22-Ko) A549 and H1299 lung cancer cells and induces a stronger activation of P53 tumor suppressor signaling pathway. In addition, USP22-Ko cancer cells are more sensitive to a combination of cisplatin and USP7. USP7 inhibitor treatment further suppresses the in vivo angiogenesis and growth and induced more apoptosis in USP22-Ko cancer xenografts. Taken together, our findings demonstrate that USP7 inhibition can dramatically upregulate USP22 in cancer cells; and targeting USP7 and USP22 may represent a more effective approach for targeted cancer therapy, which warrants further study. Citation Format: Keqiang Zhang, Ting Sun, Wendong Li, Jun Wu, Dan Raz. Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of Sp1 in human cancer cells. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3939.

USP22 Promotes NSCLC Tumorigenesis Via MDMX Up-Regulation and Subsequent P53 Inhibition.

Overexpression Of Deubiquitinating Enzyme Usp28 Promoted Non-Small Cell Lung Cancer Growth

USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression

Oncogenic USP22 Supports Gastric Cancer Growth and Metastasis by Activating C-Myc/nampt/sirt1-dependent FOXO1 and YAP Signaling

The USP21/YY1/SNHG16 Axis Contributes to Tumor Proliferation, Migration, and Invasion of Non-Small-cell Lung Cancer

USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway

Abstract 3939: Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of Sp1 in human cancer cells

Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1

USP22 promotes gefitinib resistance and inhibits ferroptosis in non‐small cell lung cancer by deubiquitination of MDM2

USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer.

Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells

USP52 inhibits cell proliferation by stabilizing PTEN protein in non-small cell lung cancer

USP21-mediated G3BP1 stabilization accelerates proliferation and metastasis of esophageal squamous cell carcinoma via activating Wnt/β-Catenin signaling

USP22 Promotes Proliferation in Renal Cell Carcinoma by Stabilizing Survivin.

Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2

USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination

USP22 promotes tumorigenesis and progression by a FKBP12/mTORC1/autophagy positive feedback loop in hepatocellular carcinoma

USP22 Mediates the Multidrug Resistance of Hepatocellular Carcinoma Via the SIRT1/AKT/MRP1 Signaling Pathway

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

Ubiquitin-specific peptidase 28 enhances STAT3 signaling and promotes cell growth in non-small-cell lung cancer.

Ubiquitin-specific Protease 22 Acts As an Oncoprotein to Maintain Glioma Malignancy Through Deubiquitinating B Cell-Specific Moloney Murine Leukemia Virus Integration Site 1 for Stabilization.